Is This Dividend Stock a Buy for Income Investors?
Rising interest rates and fears of an economic slowdown have resulted in a 24% year-to-date dip in the Nasdaq Composite.
Unsurprisingly, value stocks have performed exceptionally well so far this year as investors ran for cover amid the market volatility. This explains how pharma stock Bristol-Myers Squibb (NYSE: BMY) has rallied 22% year to date. But is the stock still a buy? Let's dive into Bristol-Myers' fundamentals and valuation to find out.
Image source: Getty Images.
Source Fool.com
